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The data described herein are related to the article entitled “Tumor
necrosis factor-α regulates triggering receptor expressed on myeloid
cells-1-dependent matrix metalloproteinases in the carotid plaques
of symptomatic patients with carotid stenosis” (Rao et al., 2016) [1].
Additional data are provided on the dose–response effect of TNF-α,
TREM-1 antibody and recombinant rTREM-1/Fc fusion chimera
(TREM-1/FC) on the expression of MMP-1 and MMP-9 in vascular
smooth muscle cells (VSMCs) isolated from human carotid endar-
terectomy tissues. Data are also presented on the distribution of
CD86þ M1- and CD206þ M2-macrophages and their co-
localization with TREM-1 in symptomatic carotid plaques as visua-
lized by dual immunoﬂuorescence. The interpretation of this data
and further extensive insights can be found in Rao et al. (2016) [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Health sciences
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acquiredFluorescent microscope (Olympus BX51), Real-time PCR systemmodel CFX96
(BioRad Laboratories, Herculus, CA). Image analysis: ImageJ prosoftwareata format Analyzed
xperimental
factorsVSMCs and carotid endarterectomy tissuesxperimental
featuresThe isolated VSMCs were treated with TNF-α with or without TREM-1
antibody and recombinant rTREM-1/Fc fusion chimera (TREM-1/FC). qPCR
was used for mRNA expression and protein expression by immuno-
ﬂuorescence studies.ata source
locationDepartment of Clinical and Translational Science, Creighton University
School of Medicine, Omaha, NE 68178ata accessibility Data within the articleValue of the data
 The data provide the information on the dose–response effect of TNF-α on the expression of TREM-
1, MMP-1 and MMP-9. This information can be used by the researchers to select a dose for their
experiments.
 Data are also presented to provide information on the individual dose–response effect of both
TREM-1 antibody (4–20 ug/ml) and TREM-1 decoy receptor rTREM-1/Fc (0.2–1.6 μg/ml) on the
expression of TREM-1, MMP-1 and MMP-9 in TNF-α -treated VSMCs. Such information is valuable
to the scientiﬁc community/researchers to select a dose for their experiments.
 Data are also presented on the relative distribution of CD86þ M1- and CD206þ M2-macrophages
and their co-localization with TREM-1 as visualized by dual immunoﬂuorescence.1. Data
In Fig. 1, data show the dose–response effect of TNF-α (5, 10 and 15 ng/ml) on the expression of
TREM-1, MMP-1 and MMP-9. Data are also presented on the individual dose-dependent effect of both
recombinant rTREM-1/Fc fusion chimer (0.2, 0.8, and 1.6 mg/ml) and TREM-1 antibody (4, 12 and
20 mg/ml) on the expression of MMP-1 and MMP-9 in VSMCs isolated from AS and S carotid plaques
treated with 10 ng/ml of TNF-α (Figs. 2 and 3). Data are also presented on the expression of TREM-1 in
CD68þ M1-macrophages and CD206þ M2-macrophages (Fig. 4).entrations of TNF-α (5, 10 and 15 ng/ml) treatment for 24 h on the expression of TREM-1, MMP-1
AS and S carotid plaques. The RNA samples isolated from the VSMCs were subjected to qPCR. Panel
and Panel C, MMP-9. Data are presented as mean7SD (N¼3). Relative expression was normalized
.01, ***po0.001, ****po 0.0001.
Fig. 2. Dose-dependent effect of recombinant rTREM-1/Fc fusion chimera (TREM-1/FC) (0.2, 0.8 and 1.6 mg/ml) on the
expression of MMP-1 (Panel A) and MMP-9 (Panel B) in VSMCs isolated from asymptomatic (AS) and symptomatic (S) carotid
plaques and treated with TNF-α (10 ng/ml). Data are presented as mean7SD (N¼3). Relative expression was normalized to
GAPDH. *po0.05, **po0.01, ***po0.001, ****po 0.0001.
Fig. 3. Dose-dependent effect of TREM-1 antibody (4, 12 and 20 mg/ml) on the expression of MMP-1 (Panel A) and MMP-9 (Panel
B) in VSMCs isolated from asymptomatic (AS) and symptomatic (S) carotid plaques and treated with TNF-α (10 ng/ml). Data are
presented as mean7SD (N¼3). Relative expression was normalized to GAPDH. *po0.05, **po0.01, ***po0.001, ****po 0.0001.
V.H. Rao et al. / Data in Brief 8 (2016) 230–2342322. Experimental design, materials and methods
2.1. Study subjects and acquisition of carotid endarterectomy specimens
The institutional Review Board of Creighton University approved the research protocol as
exempted. Surgical specimens of human atherosclerotic plaques from carotid artery were obtained
Fig. 4. Immunoﬂuorescence staining of TREM-1, CD86þ M1-macrophages and CD106þ M2-macrophages in tissue sections of
asymptomatic (AS) and symptomatic (S) carotid plaques. Representative images are shown for TREM-1 (red) and CD86 (green)
expression as visualized by dual immunoﬂuorescence in the tissue sections of asymptomatic (AS: Panels, A-D) and sympto-
matic (S: Panels, E-F). Co-localization of TREM-1 (red) and CD206 (green) is shown for AS (Panels I-L) and S (Panels M-P).
Density of CD86þ M1- and CD206þ M2-macrophages was counted per mm2 from 5 different tissues in each experimental
group and the data are shown in the bar graph (lower panel). Data are presented as mean7SD; N¼5. *po0.05, ***po0.001,
****po0.0001. Scale bar¼200 mm for all images.
V.H. Rao et al. / Data in Brief 8 (2016) 230–234 233anonymously from both asymptomatic (AS) and symptomatic (S) patients, who were males and
females of any ethnicity, aged 50–75 years. The carotid endarterectomy specimens were categorized
as symptomatic or asymptomatic based on the clinical symptoms (2,3).
V.H. Rao et al. / Data in Brief 8 (2016) 230–2342342.2. Isolation of VSMCs and treatment protocol
VSMCs were isolated from carotid plaques by the method previously reported by us [1–3]. VSMCs
at pre-conﬂuence were incubated with different concentrations of TNF-α at 4, 10 and 20 ng/ml for
24 h or 10 ng/ml TNF-α in the presence or absence of either recombinant rTREM-1/Fc (0.2–1.6 mg/ml)
or TREM-1 antibody (4–20 mg/ml).
2.3. Immunoﬂuorescence staining
The thin sections (5 mm) of the carotid plaque tissues embedded in parafﬁn were immunostained
with the antibodies and the immunoﬂuorescence was examined and the intensity was quantiﬁed
using Image-pro software, as reported previously [1,2].
2.4. Real-time qPCR
The Syber Green Master Mix was used to perform RT-qPCR (BioRad CFX96). Details of the primers
have been previously described [1,2]. Relative expression was normalized to GAPDH.
2.5. Inhibition of TREM-1
To examine the effect of TREM-1 inhibition, VSMCs were treated with TNF-α for 24 h in the
presence or absence of either recombinant TREM-1/Fc fusion chimera (0.2, 0.8 and 1.6 mg/ml) or
TREM-1 antibody (4, 12 and 20 mg/ml). The mRNA expression of MMP-1 and MMP-9 was analyzed by
qPCR and relative expression was normalized to GAPDH.
2.6. Statistical analysis
All data are reported as mean7SD. The Student's t-test and ANOVA were used to analyze sta-
tistical differences between the experimental groups. *po0.05, **po0.01, ***po0.001, ****po
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